It suggests that PRMT3 acts as an oncogenic factor in HCC, and targeting PRMT3 with its inhibitor, SGC707, effectively diminishes PRMT3-induced glycolysis and tumor growth, presenting a novel therapeutic approach for HCC treatment. Here, PRMT3 is linked to neoplasm.